Agoraphobia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Agoraphobia Market Outlook

Thelansis’s “Agoraphobia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Agoraphobia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Agoraphobia Overview

Agoraphobia is an anxiety disorder characterized by intense fear and anxiety in situations where escape might seem difficult. This disorder typically leads to avoiding situations like traveling in a vehicle, being alone outside the home, or being in crowded areas. Typically identified in young adults, the average age of onset for agoraphobia is in the mid to late twenties. While the specific causes of agoraphobia are not definitively known, several etiological factors have been proposed, including parental overprotectiveness, childhood fears or night terrors, early experiences of grief or bereavement, traumatic childhoods, or a genetic predisposition. Common comorbid personality types observed include dependent, obsessive-compulsive, and highly neurotic traits. The DSM-5 outlines that agoraphobia tends to be persistent and chronic, noting that without intervention, complete remission is rare and generally low, averaging around 10%. The prognosis worsens with the severity of the disorder and the presence of other comorbid conditions such as anxiety disorders, depression, personality disorders, or substance use disorders. These comorbidities significantly contribute to the distress and impairment experienced, which, in severe cases, can result in individuals becoming home-bound and heavily reliant on others. Treatment often involves Selective Serotonin Receptor Inhibitors (SSRIs) as the first-line therapy, with doses similar to those used in treating depression. Additionally, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), tricyclic antidepressants (TCAs), and benzodiazepines are also effective in managing symptoms of panic disorder and agoraphobia. Agoraphobia is linked to an elevated risk of developing major depressive disorder, persistent depressive disorder (dysthymia), and substance use disorders, further emphasizing the need for effective management and treatment strategies.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: